D J Drucker
Overview
Explore the profile of D J Drucker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
135
Citations
4828
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suba K, Patel Y, Martin-Alonso A, Hansen B, Xu X, Roberts A, et al.
Mol Metab
. 2024 Apr;
85:101947.
PMID: 38677509
Objective: Type 2 diabetes (T2D) is characterised by the loss of first-phase insulin secretion. We studied mice with β-cell selective loss of the glucagon receptor (Gcgr X Ins-1), to investigate...
2.
Muller T, Finan B, Bloom S, DAlessio D, Drucker D, Flatt P, et al.
Mol Metab
. 2019 Nov;
30:72-130.
PMID: 31767182
Background: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric...
3.
Burmeister M, Bracy D, James F, Holt R, Ayala J, King E, et al.
J Physiol
. 2012 Aug;
590(20):5245-55.
PMID: 22890715
In response to oral glucose, glucagon-like peptide-1 receptor (Glp1r) knockout (Glp1r−/−) mice become hyperglycaemic due to impaired insulin secretion. Exercise also induces hyperglycaemia in Glp1r−/− mice. In contrast to oral...
4.
Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology
Drucker D, Rosen C
Diabetologia
. 2011 Sep;
54(11):2741-4.
PMID: 21892687
Type 2 diabetes mellitus is characterised by beta cell failure, which frequently develops in the setting of insulin resistance. Inflammation contributes to the pathophysiology of type 2 diabetes by impairing...
5.
Maida A, Lamont B, Cao X, Drucker D
Diabetologia
. 2010 Oct;
54(2):339-49.
PMID: 20972533
Aims/hypothesis: Metformin is widely used for the treatment of type 2 diabetes. Although it reduces hepatic glucose production, clinical studies show that metformin may reduce plasma dipeptidyl peptidase-4 activity and...
6.
7.
Hadjiyanni I, Siminovitch K, Danska J, Drucker D
Diabetologia
. 2010 Mar;
53(4):730-40.
PMID: 20225396
Aims/hypothesis: Glucagon-like peptide-1 receptor (GLP-1R) agonists improve glucose control in animals and humans with type 1 diabetes. However, there is little information on the role of the GLP-1R in the...
8.
Hsieh J, Longuet C, BAKER C, Qin B, Federico L, Drucker D, et al.
Diabetologia
. 2009 Dec;
53(3):552-61.
PMID: 19957161
Aims/hypothesis: Glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors attenuate postprandial lipaemia through mechanisms that remain unclear. As dyslipidaemia is a contributing risk factor for cardiovascular...
9.
Estall J, Drucker D
Curr Pharm Des
. 2006 May;
12(14):1731-50.
PMID: 16712485
Glucagon and the glucagon-like peptides are derived from a common proglucagon precursor, and regulate energy homeostasis through interaction with a family of distinct G protein coupled receptors. Three proglucagon-derived peptides,...
10.
Reimann F, Maziarz M, Flock G, Habib A, Drucker D, Gribble F
J Physiol
. 2004 Dec;
563(Pt 1):161-75.
PMID: 15611035
Glucagon-like peptide-1 (GLP-1) is released from intestinal L-cells in response to nutrient ingestion. It is currently under therapeutic evaluation because it enhances insulin secretion in type 2 diabetes. Previous studies...